Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
Status:
Completed
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, single-dose study to investigate the plasma PK of
KW-6356 and its major metabolite, after a single oral dose of KW-6356, in subjects with mild
or moderate hepatic impairment and in healthy adults
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.